CRISPR Therapeutics vs Slate Medicines
CRISPR Therapeutics vs Slate Medicines, compared side by side on 18 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: CRISPR Therapeutics is on 64/100 and Slate Medicines on 41/100.
Where each one leads
CRISPR Therapeutics
- our overall score: 64/100 against 41/100
- domain rating: 67/100 against 14/100
- funding raised: $547M against $130M
Slate Medicines
- agent readiness: 51/100 against 44/100
At a glance
| Measure | CRISPR Therapeutics | Slate Medicines |
|---|---|---|
| What it is | Biotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology. | Advancing anti-PACAP therapies for the prevention of migraine and other headache disorders. |
| Category | Biotechnology, Gene Editing, Therapeutics, Pharmaceuticals | Biotechnology, Pharmaceuticals, Therapeutics, Healthcare |
| Sells toBusiness model | B2B | B2B |
| Offering | Platform | Services |
| Founded | 2013 | 2024 |
| Headquarters | Zug, Switzerland | Cambridge, United States |
| Status | Active | Active |
Size, funding and growth
| Measure | CRISPR Therapeutics | Slate Medicines |
|---|---|---|
| Total funding | $547M | $130M |
| Latest round | Series B | Series A |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | CRISPR Therapeutics | Slate Medicines |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 64/100 | 41/100 |
| Traction | 40/100 | 40/100 |
| Team | 70/100 | 30/100 |
| Search visibility | 13/100 | 14/100 |
| Quality | 88/100 | 45/100 |
| Agent readinessHow well an AI agent can read and act on the site | D (44/100) | D (51/100) |
| Domain ratingLink authority, 0-100 | 67/100 | 14/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | CRISPR Therapeutics | Slate Medicines |
|---|---|---|
| Hosting | Self Managed | Not detected |
| CDN | Not detected | Cloudflare |
| CMS | Not detected | WordPress |
| Frameworks | Jquery | Jquery |
| Analytics | Google Analytics 4 | Google Analytics 4 |
CRISPR Therapeutics vs Slate Medicines: common questions
Which is better, CRISPR Therapeutics or Slate Medicines?
On our 0-100 score CRISPR Therapeutics rates higher (64/100 against 41/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 18 data points above: read the rows that match what you are buying for.
How do CRISPR Therapeutics and Slate Medicines compare on the numbers?
CRISPR Therapeutics leads on our overall score (64/100 against 41/100), domain rating (67/100 against 14/100), funding raised ($547M against $130M). Slate Medicines leads on agent readiness (51/100 against 44/100).
Read the full CRISPR Therapeutics review and pricing or the Slate Medicines review and pricing. You can also browse other CRISPR Therapeutics alternatives we track.